Regeneron and Sanofi receive FDA ’s breakthrough therapy status for CSCC treatment with cemiplimab

US-based Regeneron Pharmaceuticals and French company Sanofi have received breakthrough therapy designation status for cemiplimab (REGN2810) from the US Food and Drug Administration (FDA) to treat cutaneous squamous cell carcinoma (CSCC).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news